GB201806084D0 - Antibodies - Google Patents

Antibodies

Info

Publication number
GB201806084D0
GB201806084D0 GBGB1806084.8A GB201806084A GB201806084D0 GB 201806084 D0 GB201806084 D0 GB 201806084D0 GB 201806084 A GB201806084 A GB 201806084A GB 201806084 D0 GB201806084 D0 GB 201806084D0
Authority
GB
United Kingdom
Prior art keywords
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1806084.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Berlin Chemie AG
Original Assignee
Berlin Chemie AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlin Chemie AG filed Critical Berlin Chemie AG
Priority to GBGB1806084.8A priority Critical patent/GB201806084D0/en
Publication of GB201806084D0 publication Critical patent/GB201806084D0/en
Priority to PCT/EP2019/059420 priority patent/WO2019197609A1/en
Priority to EP19717485.7A priority patent/EP3773917A1/en
Priority to TW108112823A priority patent/TW201943732A/zh
Priority to JP2020555884A priority patent/JP2021521201A/ja
Priority to US17/046,551 priority patent/US20210032360A1/en
Priority to CN201980025575.XA priority patent/CN111971091A/zh
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
GBGB1806084.8A 2018-04-13 2018-04-13 Antibodies Ceased GB201806084D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB1806084.8A GB201806084D0 (en) 2018-04-13 2018-04-13 Antibodies
PCT/EP2019/059420 WO2019197609A1 (en) 2018-04-13 2019-04-12 Antibodies against bst1 for preventing or treating myelodysplastic syndrome
EP19717485.7A EP3773917A1 (en) 2018-04-13 2019-04-12 Antibodies against bst1 for preventing or treating myelodysplastic syndrome
TW108112823A TW201943732A (zh) 2018-04-13 2019-04-12 預防或治療骨髓發育不良症候群之抗bst1抗體
JP2020555884A JP2021521201A (ja) 2018-04-13 2019-04-12 骨髄異形成症候群を予防または治療するためのｂｓｔ１に対する抗体
US17/046,551 US20210032360A1 (en) 2018-04-13 2019-04-12 Antibodies against bst1 for preventing or treating myelodysplastic syndrome
CN201980025575.XA CN111971091A (zh) 2018-04-13 2019-04-12 预防或治疗骨髓发育不良综合征的抗bst1抗体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1806084.8A GB201806084D0 (en) 2018-04-13 2018-04-13 Antibodies

Publications (1)

Publication Number Publication Date
GB201806084D0 true GB201806084D0 (en) 2018-05-30

Family

ID=62203296

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1806084.8A Ceased GB201806084D0 (en) 2018-04-13 2018-04-13 Antibodies

Country Status (7)

Country Link
US (1) US20210032360A1 (https=)
EP (1) EP3773917A1 (https=)
JP (1) JP2021521201A (https=)
CN (1) CN111971091A (https=)
GB (1) GB201806084D0 (https=)
TW (1) TW201943732A (https=)
WO (1) WO2019197609A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201711785D0 (en) * 2017-07-21 2017-09-06 Berlin-Chemie Ag Antibodies
CN112630438B (zh) * 2021-03-08 2021-06-22 信纳克(北京)生化标志物检测医学研究有限责任公司 抗体组合物及其筛查髓系疾病及检测免疫检查点的应用
CN119301155A (zh) * 2022-07-19 2025-01-10 百进生物科技公司 抗cd157抗体、其抗原结合片段和组合物及其制备和使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005295921A (ja) * 2004-04-14 2005-10-27 Pharma Design Inc 新規ｂｓｔ１選択的スプライシング変異体及びその用途
UA112062C2 (uk) * 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
UA114478C2 (uk) * 2011-06-28 2017-06-26 Берлін-Хемі Аг Антитіло, яке специфічно зв'язується з bst1

Also Published As

Publication number Publication date
US20210032360A1 (en) 2021-02-04
WO2019197609A1 (en) 2019-10-17
TW201943732A (zh) 2019-11-16
JP2021521201A (ja) 2021-08-26
EP3773917A1 (en) 2021-02-17
CN111971091A (zh) 2020-11-20

Similar Documents

Publication Publication Date Title
IL280780A (en) Anti-TIGIT antibodies
IL279321A (en) Anti-SIRPalpha antibody
IL280013A (en) Anti-IL36R antibodies
SG11202106214YA (en) Novel anti-ccr8 antibody
IL279352A (en) IL-11RA antibodies
IL291068A (en) Anti-cd73 antibodies
IL289112A (en) Antibodies against tigit
IL278010A (en) Antibodies to galectin 10
GB201709808D0 (en) Antibodies
GB201817172D0 (en) Antibody
GB201905150D0 (en) Ant-ige antibodies
GB202110263D0 (en) Anti-btla antibodies
IL277030A (en) Antibodies
GB201707561D0 (en) GARP-TGF-beta antibodies
ZA202101177B (en) Anti-btla antibody
IL284584A (en) Anti-tigit antibodies
GB201811368D0 (en) Antibody
SG11202102114UA (en) Anti-klrg1 antibodies
GB201900732D0 (en) Antibodies
GB201806084D0 (en) Antibodies
GB201917480D0 (en) Antibodies
IL289160A (en) Anti-angpt2 antibodies
PT4025612T (pt) Anticorpos anti-fucosil-gm1
GB2598698B (en) Affinity-maturated anti-ASICIa antibodies
GB201711785D0 (en) Antibodies

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)